Schunack W[au] - Search Results

Year	Number of Results
1965	2
1967	2
1969	2
1972	2
1973	3
1974	12
1975	13
1976	10
1977	7
1978	5
1979	5
1980	5
1981	2
1982	4
1983	5
1984	7
1985	9
1986	6
1987	9
1988	7
1989	4
1990	6
1991	9
1992	9
1993	3
1994	10
1995	11
1996	9
1997	16
1998	15
1999	10
2000	15
2001	16
2002	15
2003	14
2004	11
2005	5
2006	6
2007	3
2008	5
2009	4
2010	1
2011	2
2014	1
2022	0

1

Structure-activity relationships of histamine H1-receptor agonists.

Pertz HH, Elz S, Schunack W. Pertz HH, et al. Among authors: schunack w. Mini Rev Med Chem. 2004 Nov;4(9):935-40. doi: 10.2174/1389557043403198. Mini Rev Med Chem. 2004. PMID: 15544554 Review.

2

Developments in histamine H1-receptor agonists.

Zingel V, Leschke C, Schunack W. Zingel V, et al. Among authors: schunack w. Prog Drug Res. 1995;44:49-85. doi: 10.1007/978-3-0348-7161-7_2. Prog Drug Res. 1995. PMID: 7644667 Review. No abstract available.

3

Pharmacology of H2-receptor antagonists: an overview.

Schunack W. Schunack W. J Int Med Res. 1989;17 Suppl 1:9A-16A. J Int Med Res. 1989. PMID: 2566544 Review.

4

The histamine H3 receptor and its ligands.

Stark H, Arrang JM, Ligneau X, Garbarg M, Ganellin CR, Schwartz JC, Schunack W. Stark H, et al. Among authors: schunack w. Prog Med Chem. 2001;38:279-308. doi: 10.1016/s0079-6468(08)70096-1. Prog Med Chem. 2001. PMID: 11774797 Review. No abstract available.

5

What are the differences between the H2-receptor antagonists?

Schunack W. Schunack W. Aliment Pharmacol Ther. 1987;1 Suppl 1:493S-503S. doi: 10.1111/j.1365-2036.1987.tb00658.x. Aliment Pharmacol Ther. 1987. PMID: 2908767 Review.

6

Design of histamine H3-receptor agonists and antagonists.

Schunack W, Stark H. Schunack W, et al. Eur J Drug Metab Pharmacokinet. 1994 Jul-Sep;19(3):173-8. doi: 10.1007/BF03188918. Eur J Drug Metab Pharmacokinet. 1994. PMID: 7867658 Review.

7

[Isohistamine].

Buschauer A, Wegner K, Schunack W. Buschauer A, et al. Among authors: schunack w. Arch Pharm (Weinheim). 1984 Jan;317(1):9-14. doi: 10.1002/ardp.19843170104. Arch Pharm (Weinheim). 1984. PMID: 6703867 German. No abstract available.

8

International Union of Pharmacology. XIII. Classification of histamine receptors.

Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL. Hill SJ, et al. Among authors: schunack w. Pharmacol Rev. 1997 Sep;49(3):253-78. Pharmacol Rev. 1997. PMID: 9311023 Review. No abstract available.

9

Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists.

Stark H, Kathmann M, Schlicker E, Schunack W, Schlegel B, Sippl W. Stark H, et al. Among authors: schunack w. Mini Rev Med Chem. 2004 Nov;4(9):965-77. doi: 10.2174/1389557043403107. Mini Rev Med Chem. 2004. PMID: 15544557 Review.

10

[Pharmacologic advantages of individual cholesterol synthesis inhibitors? Prof. Dr. Dr. med. W. Schunack, Free University Berlin, elaborates on differential therapeutic considerations].

Schunack W. Schunack W. Fortschr Med. 1991 Jun 30;109(19):71-2. Fortschr Med. 1991. PMID: 1916563 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results